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Background: The Epipen® Jr and Allerject® 0.15 mg are currently the most commonly prescribed epinephrine
auto-injectors (EAIs) for the management of anaphylaxis in pediatric patients in North America and Canada. To
ensure rapid absorption, it should be administered intramuscularly into the anterolateral aspect of the thigh. We
examined whether the 12.7-mm needle length of the Epipen® Jr and Allerject® 0.15 mg is adequate for delivering
epinephrine intramuscularly in pediatric patients who weighed <15 kg.
Methods: Consecutive pediatric patients with food allergy weighing <15 kg who required an EAI were included.
Ultrasounds of the mid-anterolateral thigh were performed under minimal (min) and maximal (max) pressure.
Skin-to-muscle depth (STMD) and skin-to-bone depth (STBD) measurements were completed. Baseline characteristics
were compared between patients with a STBDmax <12.7 mm vs. ≥12.7 mm. Linear regression including variables such
as age, sex, body mass index (BMI) and race was performed. The proportion of patients with a STBDmax <12.7 mm was
compared in those weighing <10 kg vs. 10–14.9 kg.
Results: One hundred patients were included; 29 (29%) had STBDmax <12.7 mm. Height (p = 0.02) and weight (p = 0.0002)
differed significantly between the two groups. Approximately 19% of those weighing 10–14.9 kg and 60% of those <10 kg
had a STBDmax <12.7 mm. In the multivariable regression analysis, BMI was found to be a significant predictor of STBDmax.
Conclusions: A large proportion of children <15 kg prescribed an EAI is at risk of having the auto-injector administered into
bone. Since alternative EAIs with shorter needle lengths are not currently available, EAIs should be prescribed with
appropriate counselling in this population.
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Anaphylaxis has been identified as an important cause
of morbidity and mortality [1]. Although epidemiological
data on anaphylaxis are limited, a study from Spain re-
vealed an incidence of 103 episodes per 100,000 person
years [2]. A significant number of hospital admissions
are due to anaphylaxis and, although less common, death
from anaphylaxis can also occur. A recent analysis of fatal-
ities in Brazil suggests that the accuracy of diagnostic
codes using International Classification of Diseases-10* Correspondence: hlkimkw@gmail.com
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unless otherwise stated.(ICD-10) may miss a significant number of fatal anaphyl-
axis cases [3,4]. A major risk factor for death from ana-
phylaxis is the delayed use or failure to use epinephrine
[5]. One study found that in infants with anaphylaxis, only
30% received epinephrine injections [6].
Currently, it is recommended that epinephrine be ad-
ministered intramuscularly (to allow for rapid absorp-
tion) since subcutaneous delivery has been shown to
result in slower absorption [7,8]. For the outpatient
management of anaphylaxis, EAIs are generally recom-
mended. The Epipen® Jr and Allerject® 0.15 mg, for ex-
ample, are widely prescribed for pediatric patients with
anaphylaxis. These EAIs have a needle length of 12.7 mm
and are indicated for at-risk patients weighing between 15
and 30 kg [9,10]. In clinical practice, however, these EAIs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasound image of anterolateral thigh. STMDmax:
skin-to-muscle depth with maximal pressure; STBDmax: skin-to-bone
depth with maximal pressure.
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published medical statements suggesting that they can be
prescribed in children weighing 10–25 kg [11]. In children
weighing <10 kg, there are no formal guidelines or recom-
mendations supporting the use of any commercially avail-
able EAI; nonetheless, the EAIs are often prescribed in
this patient population as well.
Given the increased rate of obesity in children, there
have been concerns that the EAI needles may not be
long enough for intramuscular delivery in the pediatric
population. Results of a study performed in children not
at risk of anaphylaxis who presented to the radiology or
emergency departments of a tertiary-care hospital in
Phoenix, Arizona suggested that the needle of the EAIs
might be too short to reach the intramuscular space in a
significant number of children [12]. However, ultrasound
measurements without pressure application were used in
this study. This is a noteworthy limitation since EAIs re-
quire pressure to inject the needle.
In the present study, we sought to evaluate whether
children weighing <15 kg who are at risk of anaphylaxis
would appropriately receive the EAI into the intra-
muscular compartment. Of note, the Epipen® Jr and
Allerject® 0.15 mg are officially indicated for children
between 15 and 30 kg. But it is often prescribed in chil-
dren <15 kg because there is no clinically accepted alter-
native with a lower dose of epinephrine. Originally, we
postulated that, due to obesity, a significant number of
these children would receive the injections subcutaneously
including those <15 kg. However, with applied pressure,
we identified that some children may receive injections
into the bone since their skin-to-bone depth at maximal
pressure (STBDmax) is less than the needle length of the
EAIs (12.7 mm). Therefore, we prospectively measured
the likelihood of children <15 kg at risk of anaphylaxis
having a STBDmax less than 12.7 mm.
Methods
All of the patients’ parents or guardians provided writ-
ten, informed consent prior to participating in this study.
The Lawson Health Research Institute Research Ethics
Board at Western University in London, Ontario, Canada
approved the study.
Consecutive pediatric patients with confirmed food
allergy weighing less than 15 kg who would benefit
from EAI prescriptions in an allergist’s office were in-
cluded in this trial. The subjects were assessed from
July 2012 to November 2013. All subjects’ parents/
guardians agreed to participate in the study. An ultra-
sound on the anterolateral aspect of the right mid
thigh (the recommended site for injections with EAIs)
was performed to measure four distances of tissue
depths: skin-to-muscle depth with minimal pressure
(STMDmin), skin-to-muscle depth with maximal pressure(STMDmax), skin-to-bone depth with minimal pressure
(STBDmin) and skin-to-bone depth with maximal pres-
sure (STBDmax) (see Figure 1). The investigator applied
the pressure while performing the ultrasound measure-
ments on each subject. The estimated maximal force
was 2–8 lbs. All ultrasounds were completed by a single
physician using a Sonosite Titan® ultrasound machine.
The primary outcome variable was the proportion of
subjects with a STBDmax less than 12.7 mm. These sub-
jects may be at risk of injecting epinephrine completely
through the muscle and into the femur. Baseline charac-
teristics between patients with a STBDmax <12.7 mm
and those with a STBDmax ≥12.7 mm were analyzed and
compared using the Student’s t-test/Mann Whitney U
test for continuous variables and Chi-square/Fischer’s
exact test for categorical variables. Linear regression ana-
lysis was performed including variables such as age, sex,
race, and body mass index (BMI). The likelihood of the
STBDmax being <12.7 mm was also calculated for the pa-
tient cohorts weighing <10 kg and 10–14.9 kg.
Results
A total of 100 participants weighing <15 kg were included
in this study; 29 subjects (29%) had a STBDmax <12.7 mm
(see Figure 2). Baseline characteristics of patients with a
STBDmax <12.7 mm vs. ≥12.7 mm are compared in
Table 1. Weight (p = 0.0002) and height (p = 0.02) were
significantly different between the two groups. Interest-
ingly, mean BMI did not differ between the two compari-
son groups (p = 0.36). The mean STMD and STBD
without pressure also differed significantly between the
two groups (p < 0.05) (see Table 1). There were no patients
with STMDmax >12.7 mm.
Multivariable linear regression analysis showed BMI
(p = 0.02; Figure 3) to be significantly associated with
STBDmax pressure following adjustment for age, sex and
Figure 2 Proportion of subjects with STBDmax <12.7 mm or ≥12.7 mm.
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cantly different between the two groups, multivariable
linear regression analysis was repeated using age, sex,
race and weight as independent variables. Weight (kg)
was found to be the strongest predictor of STBDmax
(p = 0.001; Figure 4).
Table 2 and Figure 5 show the proportion of patients
with a STBDmax <12.7 mm or ≥12.7 mm according to
different weight groupings. Approximately 19% of patients
between 10 and 14.9 kg had a STBDmax <12.7 mm com-
pared with 60% of those weighing under 10 kg (p = 0.0008).
Discussion
This prospective study examined whether the length of
the EAI needles are adequate for delivering epinephrine
intramuscularly in pediatric patients at risk of ana-
phylaxis who weighed <15 kg. Importantly, although the
Epipen® Jr and the Allerject® 0.15 mg are officially indi-
cated for children between 15 and 30 kg in Canada, they
are often prescribed in children <15 kg as there is no cli-
nically available EAI that delivers a lower dose of epine-
phrine. Ultrasound measurements of the mid anterolateralTable 1 Baseline characteristics of the patient cohort
Characteristic Total Patients with STBDma
(n = 100) (n = 71)
Age (months), median (IQR) 17 (45) 18 (45)
Males, n (%) 55 (55) 39 (55)
White race, n (%) 78 (78) 57 (80)
Weight (kg), mean (SD) 11.5 (2.2) 12.1 (1.9)
Height (m), mean (SD) 0.84 (0.1) 0.85 (0.1)
BMI (kg/m2), mean (SD) 16.4 (1.9) 16.5 (1.9)
STMDmax (mm), mean (SD) 6.4 (1.4) 6.7 (1.4)
STMDmin (mm), mean (SD) 7.8 (1.8) 8.1 (1.8)
STBDmin(mm), mean (SD) 25.1 (4.3) 26.2 (3.8)
IQR: interquartile range; SD: standard deviation; BMI: body mass index; STMDmin: ski
maximal pressure; STBDmin: skin-to-bone depth with minimal pressure; STBDmax: skithigh were performed with pressure application to
simulate the pressure required to inject an auto-injector.
Although we originally believed that a significant propor-
tion of these children was at risk of receiving the auto-
injector subcutaneously (rather than intramuscularly) due
to obesity, we found that a significant proportion of these
children were at risk of receiving the auto-injectors into
the bone. Physicians should be aware of this potential risk.
Currently, there are no published clinical studies asses-
sing whether the 12.7-mm length of the EAI needles are
adequate for delivering epinephrine intramuscularly in
pediatric patients weighing <15 kg at risk of anaphylaxis.
All of our subjects had a STMDmax <12.7 mm, suggest-
ing that none of these children were at risk of having the
auto-injector administered into the subcutaneous space.
Our findings contrast those reported by Stecher et al.
[12] who identified 12% of children weighing <30 kg that
were at risk of receiving the EAI into the subcutaneous
space. Age and BMI correlated with STMD in these chil-
dren. It is important to note that this study enrolled
children (1–12 years of age) presenting to the radiology
or emergency departments of a tertiary-care hospital in
a non-consecutive fashion. Subjects were not at risk of
anaphylaxis, and ultrasounds with pressure and mea-
surements to the femur were not completed. Almost half
of the study population was Hispanic and children who
weighed <15 kg were not analyzed separately. Our
study, on the other hand, assessed primarily Caucasian
children <15 kg who were at risk of anaphylaxis. Also,
ultrasounds with pressure were performed to simulate
how auto-injectors are given in the “real-life” setting.
Our study found that almost 30% of children < 15 kg had
a STBDmax <12.7 mm and were therefore at risk of recei-
ving epinephrine into the bone. Patients weighing <10 kg
were at even greater risk since 60% of these subjects had a
STBDmax <12.7 mm. We believe these findings are clini-
cally important, particularly since there are currently no











n-to-muscle depth with minimal pressure; STMDmax: skin-to-muscle depth with
n-to-bone depth with maximal pressure.
Figure 3 Regression line showing the association between BMI
and STBDmax. BMI: body mass index; STBDmax: skin-to-bone depth
with maximal pressure.
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eous or intravenous epinephrine administration in patients
with anaphylaxis. However, the ethical considerations in
completing studies of this nature may be prohibitive. In
children with a history of anaphylaxis, epinephrine injected
intramuscularly compared to subcutaneously has been
shown to lead to higher serum epinephrine levels more
rapidly [13,14]. This more rapid peak in epinephrine levels
has been the basis for recommending intramuscular epi-
nephrine administration as the standard of care for
anaphylaxis. Intravenous or intraosseous epinephrine
is reserved for severe, life-threatening anaphylaxis with as-
sociated hypotension, airway swelling, severe bronchospasm
or inadequate response to intramuscular epinephrine. Intra-
venous epinephrine should be given at a 1/100,000 strength
at a maximum infusion rate of 10 mcg/min [1,11,15]. The
Epipen® Jr and Allerject® 0.15 mg provide a total dose of epi-
nephrine of 0.15 mg at 1/2,000 and 1/1,000 strengths re-
spectively [9,10]. These strengths are 50 and 100 times theFigure 4 Regression line showing the association between weight
and STBDmax. STBDmax: skin-to-bone depth with maximal pressure.concentration suggested for intraosseous infusion respect-
ively. Importantly, there are no studies to confirm that the
auto-injectors would penetrate through the femur of chil-
dren. But we believe the auto-injector needle would pene-
trate the bone as supported by a case report of an adult
female experiencing an accidental injection that went com-
pletely through the bone of a distal phalanx [16]. Also, the
thickness of the cortical bone of the femur has not been for-
mally studied in young children. Animal studies confirm
that intraosseous epinephrine administration leads to similar
serum epinephrine levels as intravenous administration
[17,18]. Although the intravenous or intraosseous route of
administration should be used in the appropriate clinical set-
ting, there have been reports of severe side effects with
intravenous epinephrine administration. For example,
a 29-year-old woman had a myocardial infarction after
receiving 0.1 mL of 1/10,000 intravenous epinephrine
[19]. Sullivan reported two patients who had ventricu-
lar tachycardia after receiving a 5-mL intravenous in-
jection of 1/10,000 epinephrine [20]. There is also a
report of a 5-month-old child weighing 7 kg who pre-
sented with an allergic reaction to an emergency de-
partment and received 0.7 mL of 1/1,000 subcutaneous
epinephrine twice and then 0.7 mL of 1/1,000 epineph-
rine intravenously [21]. The infant had a cardiac arrest
and could not be resuscitated. Although these reports
involve cases where epinephrine was given at higher
doses or concentrations than currently recommended,
they illustrate the potential risks of intravenous and
intraosseous epinephrine.
Children weighing <15 kg with a STBDmax <12.7 mm
who are prescribed an EAI are at risk of injecting a more
concentrated and higher-than-recommended dose of
epinephrine into the intraosseous space. There are vari-
ous strategies that might be considered to help the clin-
ician to deal with this issue. Ideally, all children requiring
an EAI should have a STBDmax measurement with ultra-
sound to identify those who may be at risk of intraosseous
administration. In at-risk children, other forms of in-
jectable epinephrine could be considered, such as the
provision of separate syringes (with variable needle
lengths) and vials of epinephrine. However, one study
suggests that the parents of these children may not be
able to draw up the proper doses of epinephrine reli-
ably in a reasonable timeframe to manage anaphylaxis
[13]. Another strategy would be to instruct the child’s
parent or care provider to squeeze the leg and muscle
at the site of injection so that the EAI does not com-
press the muscle. In most patients, we believe this
would lead to intramuscular injection. If using this
strategy, persons injecting must be cautious not to in-
ject the device into their own hand. Manufacturers
should also consider developing auto-injectors with
variable needle lengths (and doses) and/or devices that
Table 2 Proportion of subjects with STBDmax less than or ≥12.7 mm according to weight
Weight (kg) No. of patients with
STBDmax ≥12.7 mm
Number of patients with
STBDmax <12.7 mm
P value P value
n (%) n (%)
<10 10 (40) 15 (60) 0.0002 0.0008
10 to 14.9 61 (81) 14 (19) 0.0002
STBDmax: skin-to-bone depth with maximal pressure.
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increase the likelihood of intramuscular injection. More
thorough studies assessing the pharmacokinetics and
pharmacodynamics of injecting epinephrine into the peri-
osteum, cortical bone or intraosseous space are also
required.
The main strengths of this study were that the patient
cohort included children at risk of anaphylaxis who
weighed <15 kg, the STBDmax was used as the primary
variable, and ultrasound measurements were taken in
the proper location for EAI application. The findings of
this research reveal a potential shortcoming in our
current approach to anaphylaxis.
One limitation of this study was that it was performed
in only one clinic. It is possible that the findings may dif-
fer if utilizing a multicentre study design. Therefore, we
suggest that a similar study be replicated in other cen-
tres. A second limitation was that one physician per-
formed all of the ultrasound measurements in an
unblinded fashion. Nonetheless, we feel the data col-
lected were accurate since measurements were simple to
perform and easily reproducible. The ultrasound machine
included an easy-to-use tool to accurately determine theP
Figure 5 Box plots of different weight groups among the two compameasurements for each variable assessed in our study. A
third limitation is that the physician applied the maximum
pressure to the thigh without using any method of for-
mally quantifying the pressure applied with the ultrasound
probe. We believe that, in many children, “real-life” use of
the auto-injector may actually lead to more muscle com-
pression and/or an increased risk of injecting into the
bone than was noted in our study. This may occur be-
cause greater force may be applied by parents injecting
the auto-injectors, the surface area of the currently avail-
able auto-injectors are less than that of the ultrasound
probe and/or the device may be given in an area were
muscle thickness is less than that in the mid anterolateral
thigh. In future studies, we suggest that the pressures re-
quired to trigger the various types of auto-injectors be
measured and that these pressures be applied for ultra-
sound measurements. The pressure required and the depth
of muscle compression may vary for each device and, pos-
sibly, for each individual patient. A final limitation of this
study is that the data were not analyzed to address other
EAIs aside from the Epipen® Jr and the Allerject® 0.15 mg.
The risk is likely similar for injection into the bone with
the Epipen® Jr and the Allerject® 0.15 mg. But the surface=0.0008
rison groups.
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affect the depth of injection. These products as well as
products that become available later should be compared
in future studies.
Conclusions
A significant proportion of children weighing under
15 kg who require a prescription for an EAI is at risk of
receiving epinephrine injections into the bone. Given
this risk, EAIs should be prescribed with caution in this
patient population. At this time, there are no alternative
EAIs with needle lengths shorter than 12.7 mm. We rec-
ommend further research in this area using larger pa-
tient cohorts and multicentre study designs.
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